معرفی
Adi Barzel serves as an Associate Professor at the School of Neurobiology, Biochemistry and Biophysics within Tel Aviv University's Faculty of Life Sciences. He concurrently holds leadership roles as President of The Israeli Society for Gene and Cell Therapy and head of the Varda and Boaz Dotan Center for Advanced Therapies (a collaboration between Tel Aviv University and Tel Aviv Sourasky Medical Center), while co-founding biotechnology enterprises LogicBio Therapeutics (NASDAQ: LOGC) for rare disease therapeutics and Tabby Therapeutics for B cell engineering against cancer and infectious diseases.
His academic credentials include:
- PhD in Genetics from Tel Aviv University under Professor Martin Kupiec
- Postdoctoral training in Gene Therapy at Stanford University with Professor Mark Kay
- Summa Cum Laude graduation from Tel Aviv University's Adi Lautman interdisciplinary program for outstanding students
Barzel's research integrates Gene Therapy, Immunotherapy, and Stem Cell and Regenerative Medicine to develop translational solutions for rare diseases and oncology. His work emphasizes engineering biological systems—particularly B cells—for therapeutic delivery, bridging molecular biology with clinical applications through industry-academia partnerships.
His recognized academic achievement is:
- Summa Cum Laude undergraduate distinction
No documented student advising relationships or research grants appear in the source material, though his Dotan Center leadership implies oversight of research teams. His biotechnology ventures represent direct commercialization of laboratory innovations.
Barzel directs the Varda and Boaz Dotan Center for Advanced Therapies, coordinating regenerative medicine research between Tel Aviv University and Tel Aviv Sourasky Medical Center. This infrastructure supports his dual focus on academic discovery and therapeutic development through LogicBio and Tabby Therapeutics.
حوزههای پژوهشی
